The Past, Present, and Future of HLA Typing in Transplantation

  • Claire H. Edgerly
  • Eric T. WeimerEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1802)


The HLA region is the most polymorphic genes in the human genome and is associated with an increasing number of disease states. Historically, HLA typing methodology has been governed by phenotypic determination. This practice has evolved into the use of molecular methods such as real-time PCR, sequence-specific oligonucleotides, and sequencing-based methods. Numerous studies have identified HLA matching as a key determinate to improve patient outcomes from transplantation. Solid-organ transplants focus on HLA-DRB1 in renal organ allocation while hematopoietic cell transplants focus on HLA-A, -B, -C, -DRB1 matching. The role of HLA typing in the future will be driven by HLA expression, understanding of HLA haplotypes, and rapid HLA typing.


Single molecule sequencing NGS HLA Immunogenetics RNASeq GVHD Rejection 


  1. 1.
    Merrill JP, Murray JE, Harrison JH, Guild WR (1956) Successful homotransplantation of the human kidney between identical twins. J Am Med Assoc 160(4):277–282CrossRefPubMedGoogle Scholar
  2. 2.
    Barnard CN (1967) The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur hospital, cape town. S Afr Med J 41(48):1271–1274PubMedGoogle Scholar
  3. 3.
    Hardy JD, Webb WR, Dalton ML Jr, Walker GR Jr (1963) Lung homotransplantation in man. JAMA 186:1065–1074CrossRefPubMedGoogle Scholar
  4. 4.
    Lillehei RC, Idezuki Y, Kelly WD, Najarian JS, Merkel FK, Goetz FC (1969) Transplantation of the intestine and pancreas. Transplant Proc 1(1):230–238PubMedGoogle Scholar
  5. 5.
    Starzl TE, Brettschneider L, Penn I, Bell P, Groth CG, Blanchard H, Kashiwagi N, Putnam CW (1969) Orthotopic liver transplantation in man. Transplant Proc 1(1):216–222PubMedPubMedCentralGoogle Scholar
  6. 6.
    Phillips RA, Cowan DH (1972) Human bone marrow transplantation. Med Clin North Am 56(2):433–451CrossRefPubMedGoogle Scholar
  7. 7.
    Dausset J, Nenna A (1952) Presence of leuko-agglutinin in the serum of a case of chronic agranulocytosis. C R Seances Soc Biol Fil 146(19–20):1539–1541PubMedGoogle Scholar
  8. 8.
    Dyer PA, Claas FH (1997) A future for HLA matching in clinical transplantation. European journal of immunogenetics: official journal of the British society for histocompatibility and. Immunogenetics 24(1):17–28CrossRefGoogle Scholar
  9. 9.
    Erlich H (2012) HLA DNA typing: past, present, and future. Tissue Antigens 80(1):1–11. Scholar
  10. 10.
    Cereb N, Kim HR, Ryu J, Yang SY (2015) Advances in DNA sequencing technologies for high resolution HLA typing. Hum Immunol 76(12):923–927. Scholar
  11. 11.
    Olerup O, Zetterquist H (1992) HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39:225–235. Scholar
  12. 12.
    Speiser DE, Tiercy JM, Rufer N, Grundschober C, Gratwohl A, Chapuis B, Helg C, Loliger CC, Siren MK, Roosnek E, Jeannet M (1996) High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 87(10):4455–4462PubMedGoogle Scholar
  13. 13.
    Middleton D (1999) History of DNA typing for the human MHC. Rev Immunogenet 1(2):135–156PubMedGoogle Scholar
  14. 14.
    Lawlor DA, Zemmour J, Ennis PD, Parham P (1990) Evolution of class-I MHC genes and proteins: from natural selection to thymic selection. Annu Rev Immunol 8:23–63. Scholar
  15. 15.
    Boegel S, Lower M, Schafer M, Bukur T, de Graaf J, Boisguerin V, Tureci O, Diken M, Castle JC, Sahin U (2012) HLA typing from RNA-Seq sequence reads. Genome Med 4(12):102. Scholar
  16. 16.
    Buchkovich ML, Brown CC, Robasky K, Chai S, Westfall S, Vincent BG, Weimer ET, Powers JG (2017) HLAProfiler utilizes k-mer profiles to improve HLA calling accuracy for rare and common alleles in RNA-seq data. Genome Med 9(1):86. Scholar
  17. 17.
    Fernandez-Vina MA, Klein JP, Haagenson M, Spellman SR, Anasetti C, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, Horowitz MM, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima M (2013) Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood 121(22):4603–4610. Scholar
  18. 18.
    Greene JM, Wiseman RW, Lank SM, Bimber BN, Karl JA, Burwitz BJ, Lhost JJ, Hawkins OE, Kunstman KJ, Broman KW, Wolinsky SM, Hildebrand WH, O'Connor DH (2011) Differential MHC class I expression in distinct leukocyte subsets. BMC Immunol 12:39. Scholar
  19. 19.
    Kaur G, Gras S, Mobbs JI, Vivian JP, Cortes A, Barber T, Kuttikkatte SB, Jensen LT, Attfield KE, Dendrou CA, Carrington M, McVean G, Purcell AW, Rossjohn J, Fugger L (2017) Structural and regulatory diversity shape HLA-C protein expression levels. Nat Commun 8:15924. Scholar
  20. 20.
    Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M (2011) Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 472(7344):495–498. Scholar
  21. 21.
    Petersdorf EW, Malkki M, O'HUigin C, Carrington M, Gooley T, Haagenson MD, Horowitz MM, Spellman SR, Wang T, Stevenson P (2015) High HLA-DP expression and graft-versus-host disease. N Engl J Med 373(7):599–609. Scholar
  22. 22.
    Rene C, Lozano C, Eliaou JF (2016) Expression of classical HLA class I molecules: regulation and clinical impacts: Julia Bodmer award review 2015. HLA 87(5):338–349. Scholar
  23. 23.
    Schone B, Bergmann S, Lang K, Wagner I, Schmidt AH, Petersdorf EW, Lange V (2018) Predicting an HLA-DPB1 expression marker based on standard DPB1 genotyping: linkage analysis of over 32,000 samples. Hum Immunol 79(1):20–27. Scholar
  24. 24.
    Seliger B (2017) Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors. Cytokine Growth Factor Rev 36:49–56. Scholar
  25. 25.
    Sellares J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, de Freitas DG, Kreepala C, Hidalgo LG, Famulski KS, Halloran PF (2013) Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 13(4):971–983. Scholar
  26. 26.
    Cecka JM, Reed EF, Zachary AA (2015) HLA high-resolution typing for sensitized patients: a solution in search of a problem? Am J Transplant 15(4):855–856. Scholar
  27. 27.
    Montgomery RA, Leffell MS, Zachary AA (2013) Transplantation of the sensitized patient: histocompatibility testing. Methods Mol Biol 1034:117–125. Scholar
  28. 28.
    Zachary AA, Leffell MS (2016) HLA mismatching strategies for solid organ transplantation - a balancing act. Front Immunol 7:575. Scholar
  29. 29.
    Kamoun M, Phelan D, Noreen H, Marcus N, Klingman L, Gebel HM (2017) HLA compatibility assessment and management of highly sensitized patients under the new kidney allocation system (KAS): a 2016 status report from twelve HLA laboratories across the U.S. Hum Immunol 78(1):19–23. Scholar
  30. 30.
    Smith JM, Biggins SW, Haselby DG, Kim WR, Wedd J, Lamb K, Thompson B, Segev DL, Gustafson S, Kandaswamy R, Stock PG, Matas AJ, Samana CJ, Sleeman EF, Stewart D, Harper A, Edwards E, Snyder JJ, Kasiske BL, Israni AK (2012) Kidney, pancreas and liver allocation and distribution in the United States. Am J Transplant 12(12):3191–3212. Scholar
  31. 31.
    Stewart DE, Garcia VC, Aeder MI, Klassen DK (2017) New insights into the alleged kidney donor profile index labeling effect on kidney utilization. Am J Transplant 17(10):2696–2704. Scholar
  32. 32.
    Stewart DE, Klassen DK (2016) Kidney transplants from HLA-incompatible live donors and survival. N Engl J Med 375(3):287–288. Scholar
  33. 33.
    Stewart DE, Klassen DK (2017) Early experience with the new kidney allocation system: a perspective from UNOS. Clin J Am Soc Nephrol 12(12):2063–2065. Scholar
  34. 34.
    Stewart DE, Kucheryavaya AY, Klassen DK, Turgeon NA, Formica RN, Aeder MI (2016) Changes in deceased donor kidney transplantation one year after KAS implementation. Am J Transplant 16(6):1834–1847. Scholar
  35. 35.
    Grgic I, Chandraker A (2017) Significance of biologics in renal transplantation: past, present, and future. Curr Opin Organ Transplant 23(1):51–62. Scholar
  36. 36.
    Williams RC, Opelz G, McGarvey CJ, Weil EJ, Chakkera HA (2016) The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors. Transplantation 100(5):1094–1102. Scholar
  37. 37.
    Tinckam KJ, Liwski R, Pochinco D, Mousseau M, Grattan A, Nickerson P, Campbell P (2015) cPRA increases with DQA, DPA, and DPB unacceptable antigens in the Canadian cPRA calculator. Am J Transplant 15(12):3194–3201. Scholar
  38. 38.
    Tinckam KJ, Rose C, Hariharan S, Gill J (2016) Re-examining risk of repeated HLA mismatch in kidney transplantation. J Am Soc Nephrol 27(9):2833–2841. Scholar
  39. 39.
    Roberts JP, Wolfe RA, Bragg-Gresham JL, Rush SH, Wynn JJ, Distant DA, Ashby VB, Held PJ, Port FK (2004) Effect of changing the priority for HLA matching on the rates and outcomes of kidney transplantation in minority groups. N Engl J Med 350(6):545–551. Scholar
  40. 40.
    Tinckam KJ (2012) Basic histocompatibility testing methods. pp 21–42. doi: Scholar
  41. 41.
    Eng HS, Leffell MS (2011) Histocompatibility testing after fifty years of transplantation. J Immunol Methods 369(1–2):1–21. Scholar
  42. 42.
    Crivello P, Zito L, Sizzano F, Zino E, Maiers M, Mulder A, Toffalori C, Naldini L, Ciceri F, Vago L, Fleischhauer K (2015) The impact of amino acid variability on alloreactivity defines a functional distance predictive of permissive HLA-DPB1 mismatches in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 21(2):233–241. Scholar
  43. 43.
    Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Vina M, Gandhi M, Jakubowski AA, Maiers M, Marino SR, Marsh SG, Oudshoorn M, Palmer J, Prasad VK, Reddy V, Ringden O, Saber W, Santarone S, Schultz KR, Setterholm M, Trachtenberg E, Turner EV, Woolfrey AE, Lee SJ, Anasetti C (2013) Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood 122(22):3651–3658. Scholar
  44. 44.
    Zino E, Frumento G, Marktel S, Sormani MP, Ficara F, Di Terlizzi S, Parodi AM, Sergeant R, Martinetti M, Bontadini A, Bonifazi F, Lisini D, Mazzi B, Rossini S, Servida P, Ciceri F, Bonini C, Lanino E, Bandini G, Locatelli F, Apperley J, Bacigalupo A, Ferrara GB, Bordignon C, Fleischhauer K (2004) A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood 103(4):1417–1424. Scholar
  45. 45.
    Zino E, Vago L, Di Terlizzi S, Mazzi B, Zito L, Sironi E, Rossini S, Bonini C, Ciceri F, Roncarolo MG, Bordignon C, Fleischhauer K (2007) Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13(9):1031–1040. Scholar
  46. 46.
    Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D, Maiers M (2014) HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371(4):339–348. Scholar
  47. 47.
    Tie R, Zhang T, Yang B, Fu H, Han B, Yu J, Tan Y, Huang H (2017) Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. Oncotarget 8(16):27645–27660. Scholar
  48. 48.
    Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C (2007) High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110(13):4576–4583. Scholar
  49. 49.
    Touzeau C, Gagne K, Sebille V, Herry P, Chevallier P, Follea G, Devys A, Moreau P, Mohty M, Cesbron Gautier A (2012) Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study. Hum Immunol 73(7):711–714. Scholar
  50. 50.
    Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollichieni S, Sacchi N, Sormani MP, Marcon J, Lamparelli T, Fanin R, Garbarino L, Miotti V, Bandini G, Bosi A, Ciceri F, Bacigalupo A, Fleischhauer K (2009) Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 114(7):1437–1444. Scholar
  51. 51.
    Weimer ET (2016) Clinical validation of NGS technology for HLA: an early adopter's perspective. Hum Immunol 77(10):820–823. Scholar
  52. 52.
    Weimer ET, Montgomery M, Petraroia R, Crawford J, Schmitz JL (2016) Performance characteristics and validation of next-generation sequencing for human leucocyte antigen typing. J Mol Diagn 18(5):668–675. Scholar
  53. 53.
    Lange V, Bohme I, Hofmann J, Lang K, Sauter J, Schone B, Paul P, Albrecht V, Andreas JM, Baier DM, Nething J, Ehninger U, Schwarzelt C, Pingel J, Ehninger G, Schmidt AH (2014) Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing. BMC Genomics 15:63. Scholar
  54. 54.
    Duke JL, Lind C, Mackiewicz K, Ferriola D, Papazoglou A, Gasiewski A, Heron S, Huynh A, McLaughlin L, Rogers M, Slavich L, Walker R, Monos DS (2016) Determining performance characteristics of an NGS-based HLA typing method for clinical applications. HLA 87(3):141–152. Scholar
  55. 55.
    Lind C, Ferriola D, Mackiewicz K, Heron S, Rogers M, Slavich L, Walker R, Hsiao T, McLaughlin L, D'Arcy M, Gai X, Goodridge D, Sayer D, Monos D (2010) Next-generation sequencing: the solution for high-resolution, unambiguous human leukocyte antigen typing. Hum Immunol 71(10):1033–1042. Scholar
  56. 56.
    Profaizer T, Lazar-Molnar E, Pole A, Delgado JC, Kumanovics A (2017) HLA genotyping using the Illumina HLA TruSight next-generation sequencing kits: a comparison. Int J Immunogenet 44(4):164–168. Scholar
  57. 57.
    Boza V, Brejova B, Vinar T (2017) DeepNano: deep recurrent neural networks for base calling in MinION nanopore reads. PLoS One 12(6):e0178751. Scholar
  58. 58.
    Laver TW, Caswell RC, Moore KA, Poschmann J, Johnson MB, Owens MM, Ellard S, Paszkiewicz KH, Weedon MN (2016) Pitfalls of haplotype phasing from amplicon-based long-read sequencing. Sci Rep 6:21746. Scholar
  59. 59.
    Ammar R, Paton TA, Torti D, Shlien A, Bader GD (2015) Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes. F1000Res 4:17. Scholar
  60. 60.
    Albrecht V, Zweiniger C, Surendranath V, Lang K, Schofl G, Dahl A, Winkler S, Lange V, Bohme I, Schmidt AH (2017) Dual redundant sequencing strategy: full-length gene characterisation of 1056 novel and confirmatory HLA alleles. Hla 90(2):79–87. Scholar
  61. 61.
    Chen Q, Luo G, Zhang X (2017) MiR-148a modulates HLA-G expression and influences tumor apoptosis in esophageal squamous cell carcinoma. Exp Ther Med 14(5):4448–4452. Scholar
  62. 62.
    Jain M, Fiddes IT, Miga KH, Olsen HE, Paten B, Akeson M (2015) Improved data analysis for the MinION nanopore sequencer. Nat Methods 12(4):351–356. Scholar
  63. 63.
    Jain M, Olsen HE, Paten B, Akeson M (2016) The Oxford Nanopore MinION: delivery of nanopore sequencing to the genomics community. Genome Biol 17(1):239. Scholar
  64. 64.
    Karlsson E, Larkeryd A, Sjodin A, Forsman M, Stenberg P (2015) Scaffolding of a bacterial genome using MinION nanopore sequencing. Sci Rep 5:11996. Scholar
  65. 65.
    Loose M, Malla S, Stout M (2016) Real-time selective sequencing using nanopore technology. Nat Methods 13(9):751–754. Scholar
  66. 66.
    Manrao EA, Derrington IM, Laszlo AH, Langford KW, Hopper MK, Gillgren N, Pavlenok M, Niederweis M, Gundlach JH (2012) Reading DNA at single-nucleotide resolution with a mutant MspA nanopore and phi29 DNA polymerase. Nat Biotechnol 30(4):349–353. Scholar
  67. 67.
    Norris AL, Workman RE, Fan Y, Eshleman JR, Timp W (2016) Nanopore sequencing detects structural variants in cancer. Cancer Biol Ther 17(3):246–253. Scholar
  68. 68.
    Bolisetty MT, Rajadinakaran G, Graveley BR (2015) Determining exon connectivity in complex mRNAs by nanopore sequencing. Genome Biol 16:204. Scholar
  69. 69.
    Branton D, Daniel B, Deamer DW, Andre M, Hagan B, Benner SA (2008) The potential and challenges of nanopore sequencing. Nat Biotechnol 26(10):1146–1153. Scholar
  70. 70.
    Wei S, Williams Z (2016) Rapid short-read sequencing and aneuploidy detection using MinION Nanopore technology. Genetics 202(1):37–44. Scholar
  71. 71.
    Clarke J, Wu HC, Jayasinghe L, Patel A, Reid S, Bayley H (2009) Continuous base identification for single-molecule nanopore DNA sequencing. Nat Nanotechnol 4(4):265–270. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory Medicine, School of MedicineUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations